{
    "2021-04-21": [
        [
            {
                "time": "2021-04-21",
                "original_text": "晚间重要公告2021年4月21日星期三",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "仿制药",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "国际基金巨头大幅增持恒瑞医药 孙飘扬个人斥3.16亿加码新药公司",
                "features": {
                    "keywords": [
                        "国际基金",
                        "增持",
                        "孙飘扬",
                        "新药公司"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "股价暴跌 恒瑞医药董事长首次这样回应集采问题 连续下跌",
                "features": {
                    "keywords": [
                        "股价暴跌",
                        "集采",
                        "董事长"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "首创证券---恒瑞医药：全年业绩符合预期，今年机遇与挑战并存【公司研究】",
                "features": {
                    "keywords": [
                        "首创证券",
                        "恒瑞医药",
                        "业绩",
                        "预期"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "A股资金流向（4月21日）：医美龙头获青睐，华为汽车概念遭抛售",
                "features": {
                    "keywords": [
                        "A股",
                        "资金流向",
                        "医美",
                        "华为汽车"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "渤海证券---医药行业周报：药品与耗材国采推进，结合估值与业绩探寻机会【行业研究】",
                "features": {
                    "keywords": [
                        "渤海证券",
                        "医药行业",
                        "国采",
                        "估值",
                        "业绩"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-04-21",
                "original_text": "融券潮高峰已至，中芯国际、恒瑞医药、招商位列融券余额榜前三",
                "features": {
                    "keywords": [
                        "融券",
                        "中芯国际",
                        "恒瑞医药",
                        "招商"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "科技",
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}